Is the 'A' in atypical really due to α2-adrenoceptor antagonism? A comment on: Putting the 'A' in atypical: does α2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?

Abstract

Keywords

olanzapine clozapine atypical antipsychotic

Get full access to this article

View all access options for this article.

References

Beasley C.M. , Tollefson G. , Tran P. , Satterlee W. , Sanger T. , Hamilton S. , The Olanzapine HGAD Study Group (1995) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology (in press)

Bymaster F.P. , Calligaro D.O. , Falcone J.F. , Marsh R.D. , Moore N.A. , Tye N.C. , Seeman P. , Wong D.T. (1995) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology (in press)

Moore N.A. , Tye N.C. , Axton M.S. , Risius F.C. (1992) The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 262: 545-551

Moore N.A. , Rees G. , Sanger G. , Tye N.C. (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5: 196-202

Nutt D.J. (1994) Putting the 'A' in atypical: does α2 adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics ? J Psychopharmacol 8: 193-195